SNO Annual Meeting

A chimeric antigen receptor T-cell therapy used in patients with EGFRvIII-positive glioblastoma multiforme during a pilot study showed promising results, according to two leading researchers in the field presenting at the 2015 Society of Neuro-Oncology Annual Meeting.

An international team of experts is planning an innovative clinical trial to speed up development of new treatments for glioblastoma multiforme.

Developing safe and effective therapies for malignant brain tumors, specifically glioblastoma, is a challenging-yet-achieveable endeavor pursued by researchers and patients alike.

Amy Heimberger, MD, professor in the Department of Neurosurgery, University of Texas MD Anderson Cancer Center, talks about immunotheraputics in the context of glioblastoma (GBM).

A quarter of patients with relapsed glioblastoma multiforme (GBM)-treated with the vaccine rindopepimut (Rintega) plus bevacizumab remained alive at 2 years.

Phase II findings have shown a substantial improvement in overall survival with the dendritic vaccine ICT-107 in a subgroup of patients with HLA-A2+ newly diagnosed glioblastoma multiforme (GBM), warranting further exploration in a phase III study.

Though clinical work is ongoing and early, researchers are already considering how to manage potentially fatal neurotoxicities in patients treated with chimeric antigen receptor (CAR) T-cell therapy.

An emerging class of immune checkpoint blockade drugs has produced impressive benefits for patients in many solid tumor types. The class' success hints that these drugs ay be successful against central nervous system tumors as well, including glioblastoma.

Physicians are up to the task when it comes to the influx of immunotherapies being studied and approved across multiple tumor types, Jeffrey S. Weber, MD, PhD

Optune in conjunction with chemotherapy and/or bevacizumab boosted survival rates in patients with recurrent glioblastoma multiforme.

Rimas Lukas, MD, director, Medical Neuro-Oncology, co-director, Neurology Medical Student Clerkship Program, The University of Chicago Medical Center, on PD-L1 blockade treatment and its potential in patients with recurrent glioblastoma (GBM).

David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, on the need to identify glioblastoma (GBM) patients with the EGFRvIII mutation in their tumor.